



NEWS RELEASE

Foundation Medicine and ARIAD Announce Collaboration for Genomic Characterization of Patients in AP26113 Oncology Program

Collaboration will use genomic profiling to characterize patients treated with ARIAD's investigational dual-inhibitor of ALK and EGFR

CAMBRIDGE, MA. November 13, 2012 – [Foundation Medicine, Inc.](#) and [ARIAD Pharmaceuticals, Inc.](#) (Nasdaq: ARIA) today announced a genomic profiling collaboration to study AP26113, ARIAD's investigational dual-inhibitor of ALK and EGFR in patients with non-small cell lung cancer (NSCLC) and other cancers. Foundation Medicine will work with ARIAD to generate genomic profile information for patients enrolled in ARIAD's ongoing Phase 1/2 trial and these data will be matched with clinical observations to understand the activity and selectivity profile of AP26113.

“It is important that we have a deep molecular understanding of patients' tumors as they begin treatment with AP26113, especially those patients with complex prior treatment histories,” stated Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at ARIAD. “Foundation Medicine is at the forefront of genomic profiling technologies that will provide molecular insights on a wide array of clinically relevant tumor genes including ALK and EGFR alteration status. We look forward to collaborating on the AP26113 program as we move into anticipated pivotal trial(s) in 2013.”

“This study is an example of how cancer complexity often defies single-marker analysis in drug development,” said Michael Pellini, M.D., president and chief executive officer, Foundation Medicine. “We expect that our comprehensive genomic profile will help to identify the optimal patient population for AP26113 and may potentially enable an expedited development timeline.”

About ARIAD

ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD's approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant or difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. For additional information, visit <http://www.ariad.com> or follow ARIAD on [Twitter](#).

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's initial clinical product, [FoundationOne™](#), is a fully informative genomic profile to identify a patient's individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.foundationmedicine.com.

Foundation Medicine® is a registered trademark, and FoundationOne™ is a trademark, of Foundation Medicine, Inc.

Contact:**Foundation Medicine**

Dan Budwick
Pure Communications, Inc.
(973) 271-6085

For ARIAD Investors

Kendra Adams
Kendra.adams@ariad.com
(617) 503-7028

For ARIAD Media

Liza Heapes
Liza.heapes@ariad.com
(617) 621-2315

###